文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

氯沙坦对住院COVID-19诱导肺损伤患者的疗效:一项随机临床试验

Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: A Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2022-03-01
一句话结论住院COVID-19合并急性肺损伤患者口服氯沙坦50 mg每日两次未改善7天Pao2:Fio2比值,且无升压药天数更少。

这项在美国13家医院开展的盲法、安慰剂对照随机临床试验,于2020年4月至2021年2月纳入205例住院COVID-19且呼吸序贯器官衰竭评估评分至少1分、未使用RAAS抑制剂的患者,随机接受氯沙坦50 mg口服每日两次或等效安慰剂,疗程10天或至出院。主要终点7天Pao2:Fio2比值差异为-24.8(95%CI -55.6至6.1;P=0.12),未达统计学显著。氯沙坦未改善任何次要临床结局,且无升压药天数少于安慰剂组(中位9.4天 vs 8.7天)。作者认为这些数据可能对正在进行的临床试验有启示。

要点

  • 住院COVID-19合并急性肺损伤患者口服氯沙坦50 mg每日两次,7天Pao2:Fio2比值差异-24.8(95%CI -55.6至6.1;P=0.12),未达统计学显著。
  • 氯沙坦未改善任何次要临床结局,包括序贯COVID-19严重程度、无补充氧/通气/升压药天数及死亡率。
  • 氯沙坦组无升压药天数中位9.4天(IQR 9.1-9.8)少于安慰剂组8.7天(IQR 8.2-9.3)。
  • 纳入标准为呼吸序贯器官衰竭评估评分至少1分且未使用RAAS抑制剂;氯沙坦50 mg口服每日两次,疗程10天或至出院。

适用人群与场景

  • 住院COVID-19患者,呼吸序贯器官衰竭评估评分至少1分,且未使用RAAS抑制剂,来自美国13家医院。

诊断标准与关键阈值

  • 呼吸序贯器官衰竭评估评分至少1分。
  • 未使用RAAS抑制剂。

处置流程与药物剂量

  • 氯沙坦50 mg口服每日两次,疗程10天或至出院。
  • 对照组使用等效安慰剂。

研究设计与关键结果

  • 盲法、安慰剂对照随机临床试验,在美国13家医院开展,2020年4月至2021年2月纳入205例患者(平均[SD]年龄55.2[15.7]岁;男性123例[60.0%]),氯沙坦组101例,安慰剂组104例。
  • 主要终点7天插补Pao2:Fio2比值:氯沙坦与安慰剂差异-24.8(95%CI -55.6至6.1;P=0.12),未达统计学显著。
  • 氯沙坦未改善任何次要临床结局,且无升压药天数少于安慰剂组(中位[IQR] 9.4[9.1-9.8]天 vs 8.7[8.2-9.3]天)。
  • 亚组中测量了氯沙坦药代动力学及RAAS组分(AII、血管紧张素-[1-7]、血管紧张素转化酶1和2)。

证据类型、等级与局限

  • 证据类型:随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对住院COVID-19合并急性肺损伤患者,启动口服氯沙坦未改善7天Pao2:Fio2比值,且无升压药天数更少。
  • 作者认为这些数据可能对正在进行的临床试验有启示。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: SARS-CoV-2 viral entry may disrupt angiotensin II (AII) homeostasis, contributing to COVID-19 induced lung injury. AII type 1 receptor blockade mitigates lung injury in preclinical models, although data in humans with COVID-19 remain mixed.

OBJECTIVE: To test the efficacy of losartan to reduce lung injury in hospitalized patients with COVID-19.

DESIGN, SETTING, AND PARTICIPANTS: This blinded, placebo-controlled randomized clinical trial was conducted in 13 hospitals in the United States from April 2020 to February 2021. Hospitalized patients with COVID-19 and a respiratory sequential organ failure assessment score of at least 1 and not already using a renin-angiotensin-aldosterone system (RAAS) inhibitor were eligible for participation. Data were analyzed from April 19 to August 24, 2021.

INTERVENTIONS: Losartan 50 mg orally twice daily vs equivalent placebo for 10 days or until hospital discharge.

MAIN OUTCOMES AND MEASURES: The primary outcome was the imputed arterial partial pressure of oxygen to fraction of inspired oxygen (Pao2:Fio2) ratio at 7 days. Secondary outcomes included ordinal COVID-19 severity; days without supplemental o2, ventilation, or vasopressors; and mortality. Losartan pharmacokinetics and RAAS components (AII, angiotensin-[1-7] and angiotensin-converting enzymes 1 and 2)] were measured in a subgroup of participants.

RESULTS: A total of 205 participants (mean [SD] age, 55.2 [15.7] years; 123 [60.0%] men) were randomized, with 101 participants assigned to losartan and 104 participants assigned to placebo. Compared with placebo, losartan did not significantly affect Pao2:Fio2 ratio at 7 days (difference, -24.8 [95%, -55.6 to 6.1]; P = .12). Compared with placebo, losartan did not improve any secondary clinical outcomes and led to fewer vasopressor-free days than placebo (median [IQR], 9.4 [9.1-9.8] vasopressor-free days vs 8.7 [8.2-9.3] vasopressor-free days).

CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that initiation of orally administered losartan to hospitalized patients with COVID-19 and acute lung injury did not improve Pao2:Fio2 ratio at 7 days. These data may have implications for ongoing clinical trials.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04312009.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Puskarich MA, Ingraham NE, Merck LH, et al. Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: A Randomized Clinical Trial. JAMA Netw Open. 2022. PMID: 35294537. doi:10.1001/jamanetworkopen.2022.2735

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。